That strong HOOK3 expression pertained prognostic relevance even in the subset of cancers harboring PTEN deletions—one of the strongest known prognostic markers in prostate cancer [18,23,24]–further emphasizes a clinically relevant role of HOOK3 testing. This evidence concerns the gene HOOK3 and prostate cancer.